Destiny Pharma PLC Grant of Options (1162B)

TIDMDEST

RNS Number : 1162B

Destiny Pharma PLC

04 June 2019

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Grant of Options

Brighton, United Kingdom - 4 June 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that it has granted options ("Options") over 335,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (representing 0.76 per cent. of the Company's issued share capital) to certain employees of the Company, including the below Director and PDMR.

 
 Name              Position           Options Issued   Total Options 
                                                        Held Post Issue 
                   Chief Executive 
 Neil Clark         Officer           200,000          544,305 
 Jesus Gonzales    PDMR               75,000           75,000 
 

The Options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantage options. The Options have been granted at a price of GBP0.01 per Ordinary Share, which will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[e-mail]

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail]

[phone]

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Neil Clark 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief Executive Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Destiny Pharma plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800O9WH9Z38EHAC95 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the               Options over ordinary shares of 
       Financial instrument,            1 pence each ("Ordinary Shares") 
       type of instrument 
      Identification code              DEST GB00BDHSP575 
     -------------------------------  ---------------------------------- 
 b)   Nature of the transaction        Grant of Options 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)           1 pence per Ordinary Share 
                                        200,000 Ordinary Shares 
     -------------------------------  ---------------------------------- 
 d)   Aggregated information: 
       Aggregated volume                 See 4c) above 
       Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          4 June 2019 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange, AIM Market 
     -------------------------------  ---------------------------------- 
 
 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Jesus Gonzales 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chief Executive Officer 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Destiny Pharma plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800O9WH9Z38EHAC95 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the               Options over ordinary shares of 
       Financial instrument,            1 pence each ("Ordinary Shares") 
       type of instrument 
      Identification code              DEST GB00BDHSP575 
     -------------------------------  ---------------------------------- 
 b)   Nature of the transaction        Grant of Options 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)           1 pence per Ordinary Share 
                                        75,000 Ordinary Shares 
     -------------------------------  ---------------------------------- 
 d)   Aggregated information: 
       Aggregated volume                 See 4c) above 
       Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          4 June 2019 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange, AIM Market 
     -------------------------------  ---------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBXGDLLXGBGCS

(END) Dow Jones Newswires

June 04, 2019 09:39 ET (13:39 GMT)